Israeli man facing early-onset Alzheimer's develops potential treatment for Parkinson's disease
Initially turned away, Ofer Shina built X-tosis around Prof. Varda Shoshan-Barmatz's research. The startup has a $2.74 million Michael J. Fox Foundation grant and is initially targeting Parkinson's
Assessment
An Israeli man diagnosed with early-onset Alzheimer's channeled his condition into building a biotech startup rather than accepting a dead end. X-tosis, built on academic research from Prof. Varda Shoshan-Barmatz, now holds a $2.74 million grant from the Michael J. Fox Foundation. The company is initially aiming at Parkinson's disease, not Alzheimer's. The personal stake here is unusually direct: the founder is developing a treatment while living with a related neurodegenerative condition. Watch whether X-tosis can move from grant-funded research to clinical trials, and whether the same mechanism might eventually apply back to Alzheimer's.

